Decoding Neurological Disease. Building Precision Medicines.

CELLTIUM is developing precision therapeutics for CMT1A and related rare neurological disorders. Powered by its proprietary PRECISION™ platform, CELLTIUM translates biological insight into targeted, disease-modifying drug candidates.

CELLTIUM has built an integrated neurotherapeutics engine that combines disease-relevant models, quantitative phenotyping, multimodal data, and AI/ML to accelerate target discovery and lead development.

The precision pipeline is designed to address the core biology of CMT1A and related inherited peripheral neuropathies. Its goal is to move beyond symptom management toward therapies that preserve or restore peripheral nerve function.

CELLTIUM welcomes strategic partnerships with biopharma companies, investors, and patient advocacy organizations to advance the CMT1A pipeline and extend the reach of the PRECISION™ platform across rare neurology.